In pharmaceuticals, test results are everything and addiction specialist Indivior (INDV) has demonstrated that perfectly this week. The group's shares initially rocketed more than 20 per cent following a positive outcome for final phase testing of its new opioid addiction product, known as RBP-6000, which is used to treat patients who are addicted to opioids, alongside a wider counselling and psychosocial treatment plan.
IC TIP:
Hold
at
345p
The group still has to collate the final data and submit this to the US Food and Drug Administration. A possible product launch is on the cards for the final quarter of 2017.
